Rafael Madero Marroquín
@rafmaderoHeme/onc fellow @uchicagomed. Interested in leukemia. Views are my own. 🇲🇽
A novel IIT led by @CanerSaygin focused on R/R T-cell ALL/LBL is now open! It investigates the BCL2/BCLxL inhibitor LP-118 and ponatinib along with chemotherapy clinicaltrials.gov/study/NCT06207…
Excited to share some of our work!
One of our star senior fellows @rafmadero will be giving @UChicagoHemOnc Grand Rounds next week on 9/9/24!
Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL. ashpublications.org/bloodadvances/…
new paper featuring @AyaOncologist & @emdworkin focused on management of menses in patients with heme malignancies! pubmed.ncbi.nlm.nih.gov/39043214/
Our analysis of intensive chemo (IC) in CBF-AML (200 pt) is out in @e_JHaem! Kudos to lead author @AlexandraRojek We found: -similar EFS/OS betw IC + GO & IC alone -longer 3y EFS w/ IC + KIT inhibitor (85%) we eagerly await NCT02013648 results! onlinelibrary.wiley.com/doi/10.1002/jh…
Thank you @DrWendyStock and @_MDEducation for inviting me to this meeting! Learning so much from so many great speakers.
Pleased to share the final version of our @BloodAdvances paper on outcomes in pts w/ MPN-AP/BP in the current era of myeloid therapies! #mpnsm #leusm @yasminabaza1 @iyanagross1 @HJohnstonMD See the tweet below for a breakdown thread ashpublications.org/bloodadvances/…
How do pts w/ MPN-AP/BP fare in the current era of AML therapies? Check out our multi-center analysis of 202 pt in @BloodAdvances focused on this question! #mpnsm #leusm Thanks to mentor @myeloidmalig for her guidance - follow the thread for a deep dive! ashpublications.org/bloodadvances/…
The treatment landscape for lower-risk MDS with anemia is rapidly changing! Check out this state of the art review by Dr Battaglia, @cannova_joe, @rafmadero, and myself where we cover natural hx of dz, trial endpoints & treatment strategies! #mdssm pubmed.ncbi.nlm.nih.gov/38814537/
ASCO weekend this year means celebrating @UCCancerCenter’s 50th anniversary in style with some Chicago architecture! We’re grateful to be a part of this great institution and excited for the next decades to come in cancer care! #ASCO24 @UChicagoHemOnc
With the academic year wrapping up, we loved seeing the fellowship come together and talk with alumni and faculty about careers in hem/onc and research at our annual retreat, with a fabulous fellows’ dinner to cap off the day! @UChicagoHemOnc @UCCancerCenter
What happens when germline predisposition and BMT collide? There often isn’t enough time for donor germline eval before allo. We developed an institutional roadmap with some novel, practical diagnostic maneuvers @UChicagoHemOnc @michaelwd @mariamtn89 haematologica.org/haematologica/…
How do pts w/ MPN-AP/BP fare in the current era of AML therapies? Check out our multi-center analysis of 202 pt in @BloodAdvances focused on this question! #mpnsm #leusm Thanks to mentor @myeloidmalig for her guidance - follow the thread for a deep dive! ashpublications.org/bloodadvances/…
excited to share an episode of the @JCO_ASCO Podcast where I discuss updates of the LYSA and RESORT trials; these long-term outcomes and updates from these studies cement the standard set out by these studies for MCL and FL and continue to do so! @ASCO sites.libsyn.com/58526/jco-arti…
Always a great experience to work with and be mentored by @Anand_88_Patel ! Outcomes of MDS/AML patients, post-CD47 directed therapy, using VEN-combination regimens
Check out our new report led by @rafmadero! We looked at venetoclax-containing regimens in pts w/ MDS/AML prev treated w/ CD47 antibodies! While magro is no longer in development in the myeloid space, this may have implications for other CD47 therapies tandfonline.com/doi/full/10.10…
Another great year at Annual Updates from ASH for our fellows to learn the latest updates in heme malignancies, and present some of their own case-based clinical trial review! @UChicagoHemOnc @UChicagoLeuk @UChicagoCME
Check out this fantastic educational event for those in the Chicago area next week Mar 1, including presentations from our fellows @cannova_joe @rafmadero @AlexandraRojek and many of our favorite faculty members! @UChicagoHemOnc
Register for the 9th Annual Updates ASH conference to learn about the newest scientific updates and innovative treatment approaches in hematological malignancies. #ASH23 #PracticeChangingTreatments #MyelomaTherapies #HemOnc @UCCancerCenter @UChicagoHemOnc ow.ly/Aw5K50Qpo5B
We’re so proud of the outstanding oral presentation our chief fellow and @UChicagoLeuk star, @RoloffGreg, presented today at #ASH23 on his ROCCA consortium w @LoriMuffly, evaluating RWE of brexu-cel in pts with ALL! #ASHKudos @UChicagoHemOnc @UCCancerCenter
New paper published @BrJHaem! Thank you @Anand_88_Patel for guiding me through this project. Working with the @UChicagoLeuk group has been a fantastic experience!
New @BrJHaem paper alert in the midst of #ASH23! Our star fellow @rafmadero led an analysis of targeted inhibitors in ALL with FLT3 or IDH mutations! Follow along #leusm @AyaOncologist @CanerSaygin @DrWendyStock @UChicagoLeuk @UCHemOncFellows onlinelibrary.wiley.com/doi/full/10.11…
With #ASH23 just around the corner, be sure to check out the incredible work that our fellows (current and incoming!) will be presenting this weekend at ASH across the spectrum of heme malignancies! #leusm @UChicagoLeuk @RoloffGreg @AlexandraRojek @SamuelJYates @HJohnstonMD
Abstract (sciencedirect.com/science/articl… ) with @Anand_88_Patel @DrWendyStock @CanerSaygin @HJohnstonMD! Despite its recently described role in blinatumomab response, CD58 expression was NOT a predictor of morphological response to inotuzumab ozogamicin in our B-ALL cohort.
United States Trends
- 1. Mika 37,2 B posts
- 2. $CUTO 12,2 B posts
- 3. $PUMP 2.042 posts
- 4. DeVito 1.085 posts
- 5. Morning Joe 19,2 B posts
- 6. Drew Lock 1.470 posts
- 7. Tommy Cutlets N/A
- 8. Good Monday 1.695 posts
- 9. #MondayMotivation 15,9 B posts
- 10. Victory Monday 1.975 posts
- 11. DeFi 126 B posts
- 12. TABLO 7.274 posts
- 13. Ratings 21,1 B posts
- 14. Spirit Airlines 3.356 posts
- 15. #MondayVibes 2.745 posts
- 16. Joe Scarborough 19 B posts
- 17. #18Nov 3.087 posts
- 18. Mitch 124 B posts
- 19. 60 Minutes 47,5 B posts
- 20. #MondayMood 1.927 posts
Something went wrong.
Something went wrong.